ZFIN Image: Wei et al., 2020, Fig. 6

Image

Figure Caption

Fig. 6 The PRL inhibitor JMS-053 reduces Src pathway activation and inhibits T-ALL migration.

a JMS-053 reduced cell viability in T-ALL cell lines with high PRL-3 expression, evaluated by quantifying ATP production via Cell-Titer Glo, *p ≤ 0.001 or NS = not significant, compared to DMSO. b JMS-053 treatment (10 μM) for 2 h suppressed cell migration of T-ALL cells, **p < 0.001 compared to DMSO. For all, bars are the average of three experiments, each done in triplicate, ± standard deviation. c JMS-053 (10 µM) treatment increased Src phosphorylation at tyrosine 527. Blots are representative of at least three independent experiments. The numbers in the blot are relative expression normalized to total protein loaded. d Cell migration capability of PRL-3 overexpressing cells was compared between groups treated with DMSO, Src inhibitor Su6656 (2.5 μM), JMS-053 (10 μM) or in combination and showed no additive effects between Su6656 and JMS-053, NS = not significant, ***p < 0.05.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Oncogenesis